FilingReader Intelligence
King-Friend subsidiary gets FDA approval for drug site transfer
July 22, 2025 at 05:11 PM UTC•By FilingReader AI
Nanjing King-Friend Biochemical Pharmaceutical received US FDA approval to transfer manufacturing of etoposide injection from its subsidiary Meitheal Pharmaceuticals to Jianzheng Pharmaceutical in China.
The cancer treatment drug was originally approved by the FDA in 1996. The company invested RMB 2.16 million in the project.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:603707•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Nanjing King-Friend Biochemical Pharmaceutical publishes news
Free account required • Unsubscribe anytime